The physiological blood concentration of phenylalanine-proline can ameliorate cholesterol metabolism in HepG2 cells

• Published in: Bioscience, biotechnology, and biochemistry Vol. 87; no. 1; pp. 90 - 98
• Main Authors: Banno, Arata, Yamamoto, Mako, Mijiti, Maihemuti, Takeuchi, Asahi, Ye, Yuyang, Oda, Natsuki, Nishino, Nanami, Ebihara, Akio, Nagaoka, Satoshi
• Format: Journal Article
• Language: English
• Published: England 01.01.2023
• Subjects: Animals; Cholesterol - metabolism; Hep G2 Cells; Humans; Lipid Metabolism; Phenylalanine - metabolism; Phenylalanine - pharmacology; PPAR alpha - metabolism; Proline - metabolism; Proline - pharmacology; Rats; LC-TOF/MS; cholesterol; Phe-Pro; PPARα; CYP7A1
• ISSN: 1347-6947; 1347-6947
• DOI: 10.1093/bbb/zbac167

We have previously reported that the dipeptide Phe-Pro affects lipid metabolism in vivo and in vitro, but very little is known regarding the mechanism of action of Phe-Pro after it is absorbed by the intestines via PepT1. In this study, we administered a single oral dose of Phe-Pro to rats and quantified its concentration in the portal plasma using LC-TOF/MS analysis. Additionally, the physiological blood concentration of Phe-Pro was added to the lipid accumulation model of HepG2 cells to decrease intracellular cholesterol and increase the expression of CYP7A1 and PPARα mRNA levels. Moreover, we analyzed the binding of PPARα and Phe-Pro using AlphaFold2. We found that Phe-Pro is a ligand for PPARα. To the best of our knowledge, this is the first study that shows Phe-Pro to be present in the portal plasma. We found for the first time that Phe-Pro ameliorated cholesterol metabolism in HepG2 cells.